Kuros Biosciences News and Activities
Presence
Headquarters: Switzerland
Kuros Biosciences is a company listed under the stock ticker KURN (CH).
Executives
View the org chart displaying its 27 main executives
Most searched biographies at Kuros Biosciences
- Chris Fair, Director and Chief Executive Officer
- Oliver Walker, Chairman of the Audit and Risk Committee
- Clemens van Blitterswijk, Chairman of the Board
Popular executive movements at Kuros Biosciences
- Sjoerd Musters, Chief Operating Officer and General Manager, Netherlands, will leave the company on Aug. 1, 2026 (posted on May 8 2026).
- Iv Hall will join the company as Chief Operating Officer on Jun. 1, 2026 (posted on May 8 2026).
- Oliver Walker who was Director, becomes Chairman of the Audit and Risk Committee (posted on September 5 2025).
Click here to view some more movements at Kuros Biosciences
Create your alert
to follow the executive moves at Kuros Biosciences.
Biotechnology
Kuros Biosciences has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Kuros Biosciences
- Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth - Kuros Biosciences
- Annual General Meeting of Kuros Biosciences approves all resolutions - Kuros Biosciences
- Kuros Biosciences reports 51% year-over-year increase in sales in the first three months of 2026 - Kuros Biosciences
- Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025 - Kuros Biosciences
- Media & Investors - Kuros Biosciences
- https://pr.globenewswire.com/NewsArchive/View/yMcIo74vPGEVzaE59SfgWg==?iFrame=true
- Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA - Kuros Biosciences
- Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA - Kuros Biosciences
- Media & Investors - Kuros Biosciences
- Resources Archive - Kuros Biosciences
- View more press releases Close
Social media about Kuros Biosciences
- Kuros Biosciences on Wikipedia, Google News & Yahoo Finance
- Kuros Biosciences on LinkedIn, X (Twitter) & YouTube
